ArticleScience immunology2026
Rapidly acquired HIV-1 neutralization breadth in a rhesus V2 apex knockin mouse model after a single bolus immunization.
Abstract read
In one paragraph
Article in Science immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Deletions in variable region 1 of the HIV envelope accelerate V3-glycan bNAb induction in SHIV-infected rhesus macaques.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.Gene therapy · 2026Article
- Article
- Deep mining of the human antibody repertoire identifies frequent and genetically diverse CDRH3 topologies targetable by vaccination.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Germline-targeting HIV immunogen induces cross-neutralizing antibodies in outbred macaques.Immunity · 2026Article
- Early clonal dominance at priming sets the trajectory for broad HIV serum neutralization.bioRxiv : the preprint server for biology · 2026Article
- Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development.Science immunology · 2026Article
Corrections and comments
- Update of
Authors and funding
45 authors.
Amrit Raj GhoshBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-0692-4074
Rumi HabibDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2812-8263
Nitesh MishraDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-5387-0486
Ryan S RoarkAaron Diamond AIDS Research Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0003-0586-103X
Madhav AkauliyaBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.
Ali A AlbowaideyBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.
Joel D AllenSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.ORCID 0000-0003-2547-968X
Khaled AmerehDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Gabriel AvillionDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-6898-7783
Maria BottermannBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-8178-100X
Bo LiangDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Namit ChaudharyDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-2115-7731
Sean CallaghanDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-2966-994X
Jonathan DyeKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0003-2801-8053
Xuduo LiDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0009-0004-1155-142X
Jordan R Ellis-PughBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0000-4155-3566
Rohan Roy ChowdhuryDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0003-3586-571X
Nicole E JamesSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.ORCID 0009-0000-0243-3633
Xiaotie LiuBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.
Laura MaiorinoKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.ORCID 0000-0001-8217-1337
Paula M VillavicencioBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0008-2321-9669
Rebecca NedellecDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Prabhgun OberoiDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0009-0006-3446-4024
Kirsten J SowersDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0009-0005-7602-9461
Younghoon ParkDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0009-0003-5069-504X
Thavaleak PrumBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0004-6973-5053
Linette RodriguezDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.
Maria SsoziBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.
Jonathan L TorresDepartment of Integrative Structural and Computational Biology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0003-0137-8497
Agnes A WalshDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.
John E WarnerBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0001-1043-1643
Stephanie R WeldonBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0001-5384-9946
Liling XuBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0001-4477-5380
Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.ORCID 0000-0001-9933-9618
Max CrispinSchool of Biological Sciences, University of Southampton, Southampton SO17 1BJ, UK.ORCID 0000-0002-1072-2694
Andrew B WardConsortium for HIV/AIDS Vaccine Development (CHAVD), Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-7153-3769
Usha NairBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-1927-6889
Beatrice H HahnDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-9400-9887
Dennis R BurtonDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0001-6711-9864
Lawrence ShapiroAaron Diamond AIDS Research Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0001-9943-8819
Peter D KwongAaron Diamond AIDS Research Center, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0003-3560-232X
Darrell J IrvineDepartment of Immunology and Microbiology, Scripps Research Institute, La Jolla, CA 92037, USA.ORCID 0000-0002-8637-1405
Raiees AndrabiDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0001-8837-7520
George M ShawDepartments of Medicine and Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.ORCID 0000-0002-2338-4532
Facundo D BatistaBatista Lab, Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-1130-9463
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MOptimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogensR37AI150590 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Beatrice H Hahn · 2019 to 2026
$6.9MHIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodiesR01AI165080 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GEORGE M SHAW · 2021 to 2026
$6.6MB cell lineage-directed rational vaccine strategies based on CAP256SU Env-Ab co-evolutionR01AI167716 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Raiees Ahmad Andrabi · 2022 to 2026
$4.8MCombining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR61AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2021 to 2023
$4.7MCombining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodiesR33AI161818 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ANDRABI, RAIEES AHMAD, SHAW, GEORGE M · 2024 to 2025
$3.2MBill & Melinda Gates Foundation INV-041767Bill & Melinda Gates Foundation INV-046626Bill & Melinda Gates Foundation INV-064777NIAID NIH HHS R01 AI165080NIAID NIH HHS R01 AI167716NIAID NIH HHS R33 AI161818NIAID NIH HHS R37 AI150590NIAID NIH HHS R61 AI161818NIAID NIH HHS UM1 AI144462
Abstract
Current immunization strategies to elicit broadly neutralizing antibodies (bnAbs) against HIV-1 generally propose complex, multiboost regimens. In rhesus macaques, simian-human immunodeficiency virus (SHIV) infection rapidly drives the development of some bnAb classes sharing structural similarities with those in humans. Here, we generated a knockin (KI) mouse model with B cells bearing the unmutated common ancestor of a V2 apex-targeted bnAb lineage, V033-a. A single immunization with a germline-targeting native-like trimer, Q23-APEX-GT1, recapitulated the ontogeny of the mature rhesus bnAb in KI mice, including rare, disfavored somatic mutations. Resulting antibodies exhibited potent neutralization against a broad panel of heterologous HIV-1 strains. Boosting with Env escape mutant trimers further improved breadth and potency, and cryo-electron microscopy analysis revealed the structural basis for heterologous neutralization breadth. Nonhuman primate and mouse models combined with structure can serve as a platform for identifying and validating immunogens that streamline HIV vaccination regimens.
Indexed as
AIDS VaccinesAntibodies, NeutralizingHIV-1HIV AntibodiesHIV InfectionsAnimalsDisease Models, AnimalGene Knock-In TechniquesHumansImmunizationMacaca mulattaMiceMice, TransgenicAIDS VaccinesAntibodies, NeutralizingHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.